Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Smith & Nephew plc is a global medical technology company specializing in the design, manufacture, and marketing of devices and solutions used in orthopaedics, sports medicine, ear, nose and throat (ENT), and advanced wound care. The company operates within the broader medical devices and healthcare technology industries, serving hospitals, surgeons, and healthcare providers. Its primary revenue drivers are implantable orthopaedic devices, surgical equipment for minimally invasive procedures, and biologically active wound management products.
The company positions itself through a focus on restorative health, emphasizing technologies that help patients regain mobility and improve quality of life. Smith & Nephew was founded in 1856 in the United Kingdom as a family-owned pharmacy business and evolved over more than a century into a diversified medical technology company. It transitioned toward advanced medical devices in the 20th century through sustained internal development and targeted acquisitions, ultimately becoming a publicly listed multinational corporation.
Business Operations
Smith & Nephew organizes its operations into three core business segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The Orthopaedics segment generates the largest share of revenue and includes knee and hip reconstruction implants, trauma and extremities products, and robotic-assisted surgical systems. The Sports Medicine & ENT segment focuses on minimally invasive arthroscopic instruments, soft tissue repair solutions, and ENT surgical devices, while Advanced Wound Management provides products such as negative pressure wound therapy systems and advanced dressings for chronic and acute wounds.
The company operates manufacturing, research, and distribution facilities across multiple regions and sells products in both developed and emerging markets. It controls proprietary implant designs, surgical platforms, and wound therapy technologies, supported by internal R&D and clinician training programs. Smith & Nephew operates through numerous wholly owned subsidiaries and maintains long-term relationships with hospital systems and group purchasing organizations, rather than relying heavily on joint ventures.
Strategic Position & Investments
Smith & Nephew’s strategy emphasizes consistent above-market growth through innovation, portfolio optimization, and expansion in higher-growth surgical and sports medicine categories. The company has invested significantly in enabling technologies such as robotic-assisted surgery and digital surgical planning, including its proprietary orthopaedic robotics platform. These initiatives are intended to deepen surgeon engagement and increase procedural adoption across core orthopaedic franchises.
Historically, the company has pursued bolt-on acquisitions to strengthen its technology base and product breadth, including the acquisition of ArthroCare Corporation, which expanded its sports medicine and arthroscopy capabilities. Smith & Nephew continues to invest in product line extensions, emerging surgical techniques, and biologics-adjacent wound care solutions, while periodically divesting non-core or underperforming assets to sharpen strategic focus.
Geographic Footprint
Smith & Nephew is headquartered in London, United Kingdom, and operates on a global scale with commercial and manufacturing activities spanning North America, Europe, Asia-Pacific, Latin America, and parts of Africa and the Middle East. North America represents the company’s largest single market, particularly for orthopaedic reconstruction and sports medicine products, while Europe remains a significant base for both revenue and operational infrastructure.
The company maintains a growing presence in emerging markets, including China, India, and Brazil, where rising healthcare spending and increased access to surgical care support long-term demand. Its global footprint allows Smith & Nephew to balance mature market stability with faster-growing international regions, supported by localized sales forces and regional manufacturing capabilities.
Leadership & Governance
Smith & Nephew is led by an executive management team with experience across global medical technology and healthcare sectors. The leadership emphasizes disciplined capital allocation, operational efficiency, and innovation-driven growth, with a stated strategic vision centered on restoring patients’ mobility and health outcomes through advanced medical technologies.
Key executives include:
- Deepak Nath – Chief Executive Officer
- Anne‑Françoise Nesmes – Chief Financial Officer
- Alistair How – Executive Vice President and Chief Commercial Officer
- Craig McDonald – Executive Vice President, Global Orthopaedics
- Namrata Singh – Executive Vice President, Chief Legal and Corporate Affairs Officer
The company operates under a unitary board structure consistent with UK governance standards, combining executive leadership oversight with independent non-executive directors responsible for governance, risk management, and shareholder accountability.